Kura Oncology And Kyowa Kirin Announce Blood Publication Of Phase 1 Ziftomenib Combination Data Showing 87% ORR In Venetoclax-Naïve R/R NPM1-m AML

뉴스 본문을 불러오고 있어요.

Kura Oncology And Kyowa Kirin Announce Blood Publication Of Phase 1 Ziftomenib Combination Data Showing 87% ORR In Venetoclax-Naïve R/R NPM1-m AML | 웨이프 WAPE

Kura Oncology And Kyowa Kirin Announce Blood Publication Of Phase 1 Ziftomenib Combination Data Showing 87% ORR In Venetoclax-Naïve R/R NPM1-m AML

기사 요약

관련 종목

댓글 —